Allogene Therapeutics CFO Geoffrey Parker sells $48,698 in stock

Allogene Therapeutics' CFO Geoffrey Parker sold 36,342 shares of the company's stock on October 21, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. The transaction occurred as the stock price hovered around $1.25, reflecting a 46% decline over the past six months and nearing its 52-week low of $1.04.

Despite this recent sale, Parker's direct ownership of the company's common stock remains substantial at 1,045,877 shares, accounting for the forfeiture of 195,000 shares subject to performance restricted stock units. The sale also includes 12,500 shares and 11,924 shares acquired through the employee stock purchase program. Analysts suggest the stock is undervalued based on its Fair Value analysis.

Allogene Therapeutics recently reported its Q2 2026 financial results, showing a narrower-than-expected loss with adjusted earnings of negative $0.13 per share, exceeding analyst expectations of negative $0.17 per share. Revenue increased to $4.64 million, surpassing the forecast of $2.22 million. The company's Market Outperform rating and $6.00 price target from Citizens has been maintained, highlighting progress in clinical trials, particularly in their CAR T pipeline.